Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene Ciloleucel in R/R PMBCL
NCT06912529Phase 2Terminated
- Sponsor
- Universität Münster
- Start
- Mar 2025
- Primary completion
- Jul 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Universität Münster. Primary endpoint: Complete Metabolic Response at 3 months. Started Mar 2025; status: terminated.
02
Drugs
axicabtagene ciloleucel
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT06912529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06912529.